PATENT CLAIM ANALYSIS

Application Number: 16164530
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["435", "320100"]

Abstract:
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Claim (Index 37):
The method of  claim 36 , wherein the cancer is a solid tumor.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 97.0
- Lexical Diversity: 1.28571
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13284838', '12614282', '14071520', '15674385', '15172033']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8654634091351802
- 35 USC 102 Novelty (BERT): 0.6153678344321506
- Combined Prediction Score: 0.8404538516648772
- Mean Citation Score: 937.04142
- Max Citation Score: 965.3733
- Similarity Product: 535.8162525186002

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test